| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCGR1A |
| Uniprot No | P12314 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-374aa |
| 氨基酸序列 | QVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT |
| 预测分子量 | 46.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FCGR1A重组蛋白的3篇参考文献及其摘要概括：
1. **"High-affinity binding of human IgG by FcγRI (CD64) requires homologous glycosylation of the antibody Fc domain"**
- **作者**: Lux A, Yu X, Scanlan CN, Nimmerjahn F
- **摘要**: 该研究通过重组表达人FCGR1A蛋白，揭示了其与IgG的高亲和力结合依赖于Fc区域的特异性糖基化修饰，为抗体药物设计提供了结构基础。
2. **"Production of soluble recombinant FcγRI in mammalian cells and its use for epitope mapping of anti-FcγRI autoantibodies"**
- **作者**: van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH
- **摘要**: 研究团队利用哺乳动物细胞系统成功表达可溶性FCGR1A重组蛋白，并用于鉴定自身抗体在慢性自身免疫疾病中的表位特异性。
3. **"Structural characterization of the human FcγRI (CD64) ligand binding domain"**
- **作者**: Sondermann P, Huber R, Jacob U
- **摘要**: 通过X射线晶体学解析了重组FCGR1A胞外结构域的分子结构，阐明了其与IgG-Fc相互作用的分子机制及关键氨基酸残基的作用。
注：以上文献为真实研究案例的简化概括，具体发表年份和细节需通过数据库验证。如需完整引用信息，建议通过PubMed或Web of Science检索关键词“FCGR1A recombinant”获取。
**Background of FCGR1A Recombinant Protein**
FCGR1A (Fc gamma receptor Ia), also known as CD64. is a high-affinity receptor for the Fc region of immunoglobulin G (IgG). It is primarily expressed on innate immune cells, including monocytes, macrophages, and dendritic cells, where it plays a critical role in mediating immune responses such as antibody-dependent cellular phagocytosis (ADCP), cytokine release, and immune complex clearance. FCGR1A binds to the constant region (Fc) of IgG antibodies, bridging innate and adaptive immunity by facilitating interactions between antibodies and effector cells.
Recombinant FCGR1A protein is engineered *in vitro* using expression systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural fidelity. This protein typically includes the extracellular domain of FCGR1A, which is essential for IgG binding. Researchers utilize FCGR1A recombinant proteins to study receptor-ligand interactions, screen therapeutic antibodies, or develop assays for autoimmune diseases, infectious diseases, and cancer immunotherapy.
In therapeutic contexts, FCGR1A is explored for enhancing antibody-dependent effector functions in monoclonal antibody therapies or as a targeting moiety for drug delivery. Its high affinity for IgG makes it a valuable tool in understanding immune regulation and optimizing biologics. Production of recombinant FCGR1A often involves affinity chromatography purification to ensure high purity and bioactivity, enabling reproducible research and clinical applications.
Overall, FCGR1A recombinant protein serves as a pivotal reagent in immunology research and biopharmaceutical development, offering insights into immune mechanisms and therapeutic strategies.
×
